...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy
【24h】

Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy

机译：钠-葡萄糖共转运蛋白2抑制剂可降低经胰岛素强化治疗的2型糖尿病患者的餐时胰岛素剂量

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are anti-diabetic drugs which improve blood glucose control by blocking reabsorption of glucose from the proximal tubule of kidney. Anti-atherosclerotic properties and cardiovascular protective effects of SGLT2i have been demonstrated by recent studies; however, the efficacy and safety of addition of SGLT2i to the intensive insulin therapy remain largely unknown.Methods: We retrospectively picked up patients hospitalized for treatment of type 2 diabetes, who had been treated by the intensive insulin therapy and whose treatment using by SGLT2i started during their hospitalization. Such patients were picked up between June 2014 and May 2017 based on medical charts.Results: We found 12 eligible patients. Observation period was 10.2 ± 4.7 days, and SGLT2i was started at 12.2 ± 12.9 days after the admission. During observation period, nobody developed hypoglycemia. In spite of showing decrease of blood glucose (non-significant) before each meal, the addition of SGLT2i significantly reduced daily prandial insulin doses by approximately 4.6 units/day (-66%). The SGLT2i addition also decreased body weight by approximately 1.3 kg.Conclusion: Present study demonstrated that the addition of SGLT2i to intensive insulin therapy reduced prandial insulin doses and body weight, without the development of hypoglycemia. This result may be due to SGLT2i-mediated improvement of postprandial hyperglycemia by increasing urinary glucose excretion not via insulin secretion.J Clin Med Res. 2018;10(6):493-498doi: https://doi.org/10.14740/jocmr3392w.
机译：背景：钠葡萄糖共转运蛋白2抑制剂（SGLT2i）是抗糖尿病药物，可通过阻断肾脏近端小管对葡萄糖的重吸收来改善血糖控制。最近的研究表明了SGLT2i的抗动脉粥样硬化特性和心血管保护作用。方法：我们回顾性地选择了接受胰岛素强化治疗并开始使用SGLT2i治疗的2型糖尿病住院患者。在他们住院期间。根据病历表，在2014年6月至2017年5月之间对此类患者进行了检查。结果：我们发现了12名合格患者。观察期为10.2±4.7天，入院后的SGLT2i开始于12.2±12.9天。在观察期间，没有人发生低血糖。尽管每餐前血糖降低（不显着），但添加SGLT2i仍可将每日餐时胰岛素剂量显着降低约4.6单位/天（-66％）。结论：目前的研究表明，在强化胰岛素治疗中添加SGLT2i可以减少饮食中的胰岛素剂量和体重，而不会产生低血糖症。该结果可能是由于SGLT2i介导的通过增加尿葡萄糖排泄而不是通过胰岛素分泌来改善餐后高血糖。 2018; 10（6）：493-498doi：https://doi.org/10.14740/jocmr3392w。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号